The Role of Imaging Biomarkers Derived From Advanced Imaging and Radiomics in the Management of Brain Tumors

Faqi Shaikh 1*, Diana Dupont-Roettger 1, Jamshid Dehmeshki 1,2, Omer Awan 3, Olga Kubassova 1 and Sotirios Bisdas 4

1 Image Analysis Group, Philadelphia, PA, United States, 2 Department of Computer Science, Kingston University, Kingston-upon-Thames, United Kingdom, 3 Department of Radiology, University of Maryland Medical Center, Baltimore, MD, United States, 4 Department of Neuroradiology, University College London, London, United Kingdom

Keywords: imaging, biomarkers, radiomics, brain, tumors

INTRODUCTION

Significant advances have been made in the realm of medical image analysis in the past few decades, aimed at improving our understanding of the disease—how it develops, behaves, and responds to treatment. Advanced imaging strategies using magnetic resonance imaging (MRI) and positron emission tomography (PET) provide structural and functional phenotypic biomarkers that correlate with key disease processes. Radiomics-based biomarkers provide a deeper analysis of pathophysiological processes and insights to better diagnose, classify, stratify, and prognosticate brain tumors, and to assess their response to therapy.

Radiomics in Neuro-Oncology

Radiomics is an imaging analysis methodology that involves the extraction of quantifiable features, which serve as biomarkers for structural changes as well as pathophysiological processes in disease entities. Applying radiomics yields a numerical dataset that can be parsed, processed, and analyzed using machine learning methods (1). Radiomics-based biomarkers can provide key insights in the diagnosis, classification, and therapeutic management of various solid tumors. It is also beginning to have an impact in the management of neuro-oncological diseases, including low-grade gliomas, glioblastoma multiforme (GBM), and brain metastases (2). There is a wide spectrum of radiomics applications in this field, ranging from accurate classification of brain lesions (gliomas vs metastases, IDH-wild type vs. -mutant tumors), therapy planning (radiation therapy response prediction), and immunotherapy response assessment.

Methodology

Radiomics analysis may be performed on computed tomography (CT), magnetic resonance imaging (MRI), positron emission tomography (PET), and single-photon emission computed tomography (SPECT). Lesion identification and image segmentation are performed as the first steps and can be a manual or automated process, followed by 3D reconstruction performed on these regions of interest.

The next step is that of feature extraction and classification (FE/FC). These features are categorized as shape features (morphology-based), first-order statistics (histogram-based), and second-order statistics (texture analysis) features (3). Furthermore, higher-order statistics may also be extracted using mathematical transforms (such as Minkowski functionals, Laplace features, wavelet transforms, etc.) (4). Feature extraction produces several numerical values (depending on the imaging modality and the library used for extraction), which are then analyzed using advanced statistical or machine learning (ML) approaches, which may be supervised or unsupervised, and...
include cluster analysis, support vector machine (SVM), random forest, convolutional neural network (CNN), and deep learning neural network (DLNN) (see Figure 1) (5). The main purpose is to train a model to identify radiomics features that can serve as imaging biomarkers for disease processes. This is followed by model validation and includes methods such as $k$-fold cross-validation to test the skill of the ML model. More recent works in neuro-oncology involving DLNN have revolved around automated tumor segmentation, quantification of disease burden, pseudoprosperation assessment, multi-omics-based disease characterization, and prognostication.

**DISCUSSION**

The Current Imaging Biomarker Landscape in Neuro-Oncology

A noninvasive imaging biomarker may be described as a characteristic feature identifiable on an imaging study that indicates a key disease process. The key step is to establish these new biomarkers through correlation with ground truths, which could be the previously imaging-based “gold standards,” clinical outcomes, or pathologic evidence. There is an increasing fund of quantitative imaging biomarkers (QIB) that are catalyzing the practice of precision medicine (6). In clinical trials, the QIBs are being used as surrogate endpoints, which can significantly reduce the time and incurred costs (7). QIBs are being explored as predictive classifiers for clinical trials, which can be used for patient selection/recruitment and in the timely determination of responders vs. nonresponders.

Brain lesions are structurally and functionally complex, and there is a growing focus on noninvasive methods to study this complexity to assess the disease status. Gliomas are a heterogeneous set of tumors, based on their issue, cellular, and molecular characteristics. The role of nonimaging biomarkers in gliomas and GBMs is well known, i.e., IDH1 mutation (8) and methylguanine-DNA methyltransferase (MGMT) promoter methylation (9). However, the role of imaging biomarkers in disease stratification or management guidance of GBM is less established.

Multiple imaging biomarkers have been identified for brain metastasis from various primary tumors. Multiparametric MRI, which includes apparent diffusion coefficient (ADC) and perfusion-weighted sequences, is used extensively in the clinical management of brain tumors. Perfusion-weighted and permeability MRI have been used for detection, delineation, and therapy response assessment of malignant brain lesions (10). Dynamic susceptibility contrast-enhanced MRI (DSC-MRI) deriving relative cerebral blood volume (rCBV) and cerebral blood flow (rCBF) values have led the quantifiable image biomarker discovery (11). Higher rCBV in the peritumoral edema, which may contain infiltrating angiogenic tumor cells, is indicative of primary intrinsic tumor as opposed to pure vasogenic edema seen in metastatic disease (12). However, the evidence for ADC to do the same is weak. Also, rCBV measurement from the solid tumoral region is another established discriminative biomarker for distinguishing GBM from the other tumor types (13).

Magnetic resonance spectroscopy (MRS) allows us to assess tissue metabolites noninvasively and has yielded several biomarkers of interest, such as choline (Cho)/creatinine (Cr) ratio, which is, for example, lower in cerebral metastases than in GBMs (14). Similarly, the peritumoral Cho/NAA ratio has also been shown to be useful to that effect (15). Furthermore, decreased creatine/phosphocreatine (Cr) values in patients with low-grade gliomas (WHO grade II) have been shown to correlate with better prognosis in terms of longer progression-free times and later malignant transformation (16). High levels of glycine have been reported in biopsies of patients with GBM (17). These, among other metabolites such as lactate, have been implicated as important MRS-based biomarkers for brain tumors.

18F-Fluorodeoxyglucose (FDG) PET/CT and more recently PET/MR has traditionally had a limited role in the management of primary brain tumors, primarily due to FDG biodistribution in the brain, hence there is an increasing role for amino-acid PET tracers in neuro-oncology. 18F-Fluoro-ethyl-tyrosine (FET) has been shown to detect recurrence in previously treated glioblastomas and is influenced by MGMT promoter methylation status (18). FET-PET-based biological tumor volume in newly diagnosed GBM has been shown to be a prognostic imaging biomarker for survival, independent of MGMT promoter methylation (19). However, it is important to note that the role of this biomarker for survival outcomes modeling has not been established. High tumoral amino-acid uptake using 11C-methionine (MET) PET is another well-studied biomarker for malignant gliomas and is independently associated with poor prognosis (20). α-[11C]Methyl-L-tryptophan PET has also been shown to predict longer overall survival (21).

Radiomics-Based Imaging Biomarkers in Neuro-Oncology: A Novel Paradigm

Radiomic signatures are providing the next-generation imaging biomarkers that have implications in the management of brain tumors. These signatures are based on combinations of first-order histogram-based features (Haralik features, kurtosis, and entropy) and second-order texture analysis features (such as gray-scale run lengths). Key areas in neuro-oncology where radiomics has been initially applied are the following:

- **Precision diagnostics and disease stratification/classification:** Since primary and metastatic brain tumors are histologically and genetically heterogeneous, and it is important to understand the role tumor heterogeneity plays in the natural history of cancer, its response to therapy, and prognosis/outcomes (22–24). The extracted radiomics features provide a numerical value for the heterogeneous tumor microenvironment changes (25). GBM is a notoriously aggressive cancer, given its therapeutic resistance and high recurrence rate, both of which have underpinnings in its molecular heterogeneity (26). Radiomics has provided insights into the tissue and molecular heterogeneity and correlated with the underlying genetic alterations (27–29). Furthermore, molecular heterogeneity of GBM at the transcriptomic level
FIGURE 1 | Radiomics features used in this study were distributed in three different techniques focused primarily on statistical approaches: (A) first-order statistics, (B) second-order statistics through the GLCM, and (C) higher-order statistics through the GLRLM. ADC, apparent diffusion coefficient; FLAIR, fluid-attenuated inversion recovery; GLCM, gray-level co-occurrence matrix; GLCMT, gray-level co-occurrence matrix transpose; GLRLM, gray-level run-length matrix; L, length of homogeneous runs for each gray level; ROI, region of interest; T1W, T1-weighted precontrast; T1W+C, T1-weighted postcontrast; T2W, T2-weighted. (Reused from Florez E, Nichols T, E Parker E, T Lirette S, Howard CM, Fatemi A. Multiparametric magnetic resonance imaging in the assessment of primary brain tumors through radiomic features: a metric for guided radiation treatment planning. Cureus. (2018) 10:e3426. doi: 10.7759/cureus.3426, under the CC-BY license).
can be assessed using radiomics and may provide a framework to classify/stratify GBMs (30). Shofty et al. (31) demonstrated the ability of radiomics analysis of multiparametric MRI to stage 1p/19q co-deleted low-grade gliomas with sensitivity, specificity, and accuracy of 92, 83, and 87%, respectively (31). There is an interest in reclassifying many cancer types from the conventional histological basis to that based on radiogenomic signatures shedding light into various tissue heterogeneity patterns as they are better aligned with therapeutic responsiveness (32, 33).

- **Disease prognostication and prediction modeling:** There are multiple prognostic determinants for brain tumors, including the histologic subtype, specific genetic mutations, degree of anaplasia, degree of necrosis of fibrosis, degree of differentiation, local infiltration, vasculogenesis and resulting vascular scavenging, and hypoxia. For most of these processes, radiomics analysis can provide a degree of quantification, such as wavelet transforms for the degree of vascularity or Minkowski functionals for the degree of necrosis (34). Zhang et al. (35) demonstrated the use of Minkowski features among others to help differentiate radiation necrosis from tumor progression in patients with brain metastases undergoing gamma-knife surgery. MR-based radiomics analysis has been shown to predict overall survival and progression-free survival in GBM (36). Radiomics signatures correlate with and predict the expression of key molecular biomarkers in brain tumors, such as Ki-67 expression in low-grade gliomas or IDH mutation in GBM (37, 38). These early predictive models may provide bases of re-classifying cancers based on their progression and prognosis, allowing indolent cancers to be managed more conservatively while reserving more aggressive therapeutic approaches for more aggressive cancers. This is exemplified by a study by Davatzikos et al. where they showed that molecular features depicted by radiomics provided better risk stratification of GBM beyond the WHO classification (39). Furthermore, radiomics can help in the assessment of medical complications associated with brain tumors, such as epilepsy in patients with low-grade gliomas, which facilitates better disease management (40).

- **Therapy response assessment and monitoring:** Radiomics-based phenotype assessment of cancer lesions is an effective tool in the sensitivity profiling against therapeutic options (such as quantifying hypoxia to determine chemosensitivity), as well as an early assessment of therapy response (41–43). The standard visual assessment of radiological images for this purpose has been plagued by the confounding pseudoprogression. Current MRI techniques and human-based interpretation are tedious and prone to high interpersonal variability for accurate classification and prognostication of gliomas (44). The current Response Assessment in Neuro-oncology (RANO) criteria are used for GBM and the immunotherapy RANO (iRANO) criteria have been introduced to address the issue of pseudoresponse/pseudoprogression for both conventional chemoradiation and immunotherapies (45). Novel approaches using multiparametric MR and/or PET imaging combined with radiomics-based texture analysis can help evaluate subtle microstructural as well as functional changes at earlier time points than standard imaging (46). These can be quantifiable harbingers of true therapy response assessment and debunking pseudo-progression more accurately and earlier than conventional approaches. A multicenter study performed by Elshafeey et al. (47) using MR-based radiomics analysis for immunotherapy response assessment in GBM yielded an accuracy, specificity, and sensitivity of 91, 91, and 88%, respectively.

Radiomic tumor signatures can be incorporated into a multidimensional, multi-“omics” model, which uses genetic/molecular determinants to create a holistic genotype-phenotype the landscape of cancer and have the potential for informing the prognosis and accurately predicting/assessing therapy response (48). New approaches, such as using Multi Assay Experiment (MAE) as the container for multi-omics analysis, facilitates the process of data compilation and integration required for such complex analyses (49). Furthermore, quantitative scoring scales based on such ML-based analytical models have applications in clinical management as well as “go/no-go” decision-making in clinical trials (50, 51).

Generally speaking, there are factors that hinder the full-scale application and widespread acceptance of radiomics in the field of neuro-oncology. This includes the lack of user-friendly, FDA-approved software programs that perform radiomic analysis, the lack of a generalizable model to use for predictions, and the lack of a prospective study to show the added value of radiomics compared with the conventional ROI and histogram analysis.

Specific to its clinical application in neuro-oncologic management, there are certain gaps where radiomics has yet to make an impact. These include providing biomarkers for the precision guidance of the therapeutic management of brain tumors, particularly GBM. Genetic markers that are implicated in the prognostication and therapy guidance of GBM include gene amplification of epidermal growth factor receptor (EGFR), TP53, and PTEN mutation, among others (52, 53). Developing radiomic signatures that correlate with these genetic markers can help develop noninvasive imaging biomarkers for risk/severity stratification, survival outcomes, and therapy response prediction and assessment for these patients. Furthermore, having such radiomic biomarkers can catalyze the development of novel therapeutics using these genetic markers as targets.

The scope of radiomics applications is growing. When vetted through robust statistical analyses and real-world applications, it can augment the shift toward personalized, precision-based practices in neuro-oncology.

**AUTHOR CONTRIBUTIONS**

FS: conceptualization, subject expertise (cancer imaging + radiomics methodology). SB: subject matter expertise (clinical neuroradiology). OK: subject matter expertise
REFERENCES

1. Gillies RJ, Kinahan PE, Hricak H. Radiomics: images are more than pictures, they are data. Radiology. (2016) 278:563–77. doi: 10.1148/radiol.2015151169
2. Zhou M, Scott J, Chaudhury B, Hall L, Goldgof D, Yeom KW, et al. Radiomics in brain tumor: image assessment, quantitative feature descriptors, and machine-learning approaches. Am J Neuroradiol. (2018) 39:208–16. doi: 10.3174/ajnr.A5391
3. Parmar C, Velazquez ER, Leijenaar R, Jermoumi M, Carvalho S, Mak RH, et al. Robust radiomics feature quantification using semiautomated volumetric segmentation. PLoS One. (2014) 9:e101207. doi: 10.1371/journal.pone.0101207
4. Kumar V, Gu Y, Basu S, Berglund A, Eschrich SA, Schabath MB, et al. Radiomics: the process and the challenges. Magn Reson Imaging. (2012) 30:1234–48. doi: 10.1016/j.mri.2012.06.010
5. Parmar C, Grossmann P, Bussink J, Lambin P, Aerts HJ. Machine learning methods for quantitative radiomic biomarkers. Sci Rep. (2015) 5:13087. doi: 10.1038/srep013087
6. Larue RT, DeFraene G, De Ruyscher D, Lambin P, Van Elmpw T. Quantitative radiomics studies for tissue characterization: a review of technology and methodological procedures. Br J Radiol. (2017) 90:20160665. doi: 10.1259/bjr.20160665
7. O’Connor JP, Jackson A, Asselin MC, Buckley DL, Parker GJ, Jayson GC. Quantitative imaging biomarkers in the clinical development of targeted therapeutics: current and future perspectives. Lancet Oncol. (2008) 9:766–76. doi: 10.1016/S1470-4247(08)70196-7
8. Turkalp Z, Karamchandi J, Das S. IDH mutation in glioma: new insights and promises for the future. JAMA Neuro. (2014) 7:1319–25. doi: 10.1001/jamaneuro.2014.1205
9. Weller M, Stupp R, Reifenberger G, Brandes AA, Van Den Bent MJ, Wick W, et al. MGMT promoter methylation in malignant gliomas: ready for personalized medicine?. Nat Rev Neurol. (2010) 6:39. doi: 10.1038/nrneuro.2009.197
10. Lacerda S, Law M. Magnetic resonance perfusion and permeability imaging in brain tumors. Neuroimaging Clin. (2009) 19:527–57. doi: 10.1016/j.nic.2009.08.007
11. Paulson ES, Schmainda KM. Comparison of dynamic susceptibility-weighted contrast-enhanced MR methods: recommendations for measuring relative cerebral blood volume in brain tumors. Radiology. (2008) 249:601–13. doi: 10.1148/radiol.2492071659
12. Chiang IC, Kuo YT, Lu CY, Yeung KW, Lin WC, Sheu FO, et al. Distinction between high-grade gliomas and solitary metastases using peritumoral 3-T magnetic resonance spectroscopy, diffusion, and perfusion imaging. Neuroradiology. (2004) 46:619–27. doi: 10.1007/s00234-004-1246-7
13. Xing Z, You RX, Li J, Liu Y, Cao DR. Differentiation of primary central nervous system lymphomas from high-grade gliomas by rCBV and percentage of signal intensity recovery derived from dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. Clin Neuroradiol. (2014) 24:329–36. doi: 10.1007/s00062-013-0255-5
14. Tsougos I, Svolos P, Kouli E, Fountas K, Theodorou K, Fozoulidis I, et al. Differentiation of glioblastoma multiforme from metastatic brain tumor using proton magnetic resonance spectroscopy, diffusion and perfusion metrics at 3T. Cancer Imaging. (2012) 12:423. doi: 10.1102/1470-7330.2012.0038
15. Server A, Jøsøsen R, Kulle B, Maehlen J, Schellhorn T, Gadmar O, et al. Proton magnetic resonance spectroscopy in the distinction of high-grade cerebral gliomas from single metastatic brain tumors. Acta Radiol. (2010) 51:316–25. doi: 10.1034/j.1600-0451.2009.0428901
16. Hattingen E, Raab P, Franz K, Laneremann H, Setzer M, Gerlach R, et al. Prognostic value of choline and creatine in WHO grade II gliomas. Neuroradiology. (2008) 50:759–67. doi: 10.1007/s00234-008-0409-3
17. Choi C, Ganji SK, DeBerardinis RJ, Dimitrov JE, Pasqual JM, Bachoo R, et al. Measurement of glycine in the human brain in vivo by 1H-MRS at 3 T: application in brain tumors. Magn Reson Med. (2011) 66:609–18. doi: 10.1002/mrm.22857
18. Munck af Rosenschold P, Costa J, Engelholm SA, Lundemann MJ, Law I, Olihues L, et al. Impact of [18F]-fluoro-ethyl-tyrosine PET imaging on target definition for radiation therapy of high-grade glioma. Neuro Oncol. (2015) 17:57–63. doi: 10.1093/neuonc/nou316

Other authors contributed to the article and approved the submitted version.
34. Sanduleanu S, Woodruff HC, De Jong EE, Van Timmeren JE, Jochems A, Dubois L, et al. Tracking tumor biology with radiomics: a systematic review utilizing a radiomics quality score. Radiother Oncol. (2018) 127:349–60. doi: 10.1016/j.radonc.2018.03.033

35. Zhang Z, Yang J, Ho A, Jiang W, Logan J, Wang X, et al. A predictive model for distinguishing radiation necrosis from tumour progression after gamma knife radiosurgery based on radiomic features from MR images. Eur Radiol. (2018) 28:2255–63. doi: 10.1007/s00330-017-5154-8

36. Chaddad A, Sabri S, Niazi T, Abdulkarim B. Prediction of survival with multi-scale radiomic analysis in glioblastoma patients. Med Biol Eng Comput. (2018) 56:2287–300. doi: 10.1007/s11517-018-1858-4

37. Li Y, Qian Z, Xu K, Wang K, Fan X, Li S, et al. Radiomic features predict Ki-67 expression level survival in lower grade gliomas. J Neurooncol. (2017) 135:317–24. doi: 10.1007/s11060-017-2576-8

38. Li ZC, Bai H, Sun Q, Zhao Y, Lv Y, Zhou J, et al. Multiregional radiomics profiling from multiparametric MRI: Identifying an imaging predictor of IDH1 mutation status in glioblastoma. Cancer Med. (2018). 7:5999–6009. doi: 10.1002/cam4.1863

39. Rathore S, Akbari H, Rozyczki M, Abdullah KG, Nasrallah MP, Binder ZA, et al. Radiomic MRI signature reveals three distinct subtypes of glioblastoma with different clinical and molecular characteristics, offering prognostic value beyond IDH1. Sci Rep. (2018) 8:1–2. doi: 10.1038/s41598-018-22739-2

40. Liu Z, Wang Y, Liu X, Du Y, Tang Z, Wang K, et al. Radiomics analysis allows for precise prediction of epilepsy in patients with low-grade gliomas. NeuroImage Clin. (2018) 19:271–8. doi: 10.1016/j.nicl.2018.04.024

41. Vallières M, Kay-Rivest E, Perrin LJ, Liem X, Furstoss C, Aerts HJ, et al. Impact of genotype and morphology on the prognosis of glioblastoma. J Magn Reson Imaging. (2018) 47:604–20. doi: 10.1002/jmri.25870

42. Aerts HJ. The potential of radiomic-based phenotyping in precision medicine: beyond IDH1. Sci Rep. (2018) 8:1–2. doi: 10.1038/s41598-017-10371-5

43. Aerts HJ. The potential of radiomic-based phenotyping in precision medicine: a review. JAMA Oncol. (2016) 2:1636–42. doi: 10.1001/jamaoncol.2016.2631

44. Brandsma D, Stalpers L, Taal W, Sminia P, van den Bent MJ. Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. Lancet Oncol. (2008) 9:453–61. doi: 10.1016/S1470-2045(08)70125-6

45. Okada H, Weller M, Huang R, Finocchiaro G, Gilbert MR, Wick W, et al. Immunotherapy response assessment in neuro-oncology: a report of the RANO working group. Lancet Oncol. (2015) 16:e534–42. doi: 10.1016/S1470-2045(15)00088-1

46. Da Cruz LH, Rodriguez I, Domingues RC, Gasparretto EL, Sorensen AG. Pseudoprogression and pseudoreponse: imaging challenges in the assessment of posttreatment glioma. Am J Neuroradiol. (2011) 32:1978–85. doi: 10.3174/ajnr.A2397

47. Elshafeey N, Kotrotsou A, Hassan A, Elshafey N, Hassan I, Ahmed S, et al. Multicenter study demonstrates radiomic features derived from magnetic resonance perfusion images identify pseudoprogression in glioblastoma. Nat Commun. (2019) 10:1–9. doi: 10.1038/s41467-019-11007-0

48. Bera K, Beig N, Tiwari P. Opportunities and advances in radiomics and radiogenomics in neuro-oncology. In: International Workshop on Radiomics and Radiogenomics in Neuro-oncology. Cham: Springer (2019), p. 12–23.

49. Zanfardino M, Franzese M, Pane K, Cavaliere C, Monti S, Esposto G, et al. Bringing radiomics into a multi-omics framework for a comprehensive genotype-phenotype characterization of oncological diseases. J Transl Med. (2019) 17:337. doi: 10.1186/s12967-019-2073-2

50. Pinker K, Shitano F, Sala E, Do RK, Young RJ, Wibmer AG, et al. Background, current role, and potential applications of radiogenomics. J Magn Reson Imaging. (2018) 47:604–20. doi: 10.1002/jmri.25870

51. Bi WL, Hosny A, Schabath MB, Giger ML, Birkbak NJ, Mehrtash A, et al. Artificial intelligence in cancer imaging: clinical challenges and applications. CA Cancer J Clin. (2019) 69:127–57. doi: 10.3322/caac.21552

52. Hill C, Hunter SB, Brat DJ. Genetic markers in glioblastoma: prognostic significance and future therapeutic implications. Adv Anat Pathol. (2003) 10:212–7. doi: 10.1097/00125480-200307000-00004

53. Schmidt MC, Antweiler S, Urban N, Mueller W, Kuklik A, Meyer-Puttlitz B, et al. Impact of genotype and morphology on the prognosis of glioblastoma. J Neuropathol Exp Neurol. (2002). 61:321–8. doi: 10.1093/jnen/61.4.321

Conflict of Interest: FS, DD-R, OK, JD, and SB are full-time/part-time employees of Image Analysis Group.

The remaining author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2020 Shaikh, Dupont-Roettger, Behmedski, Awan, Kubasova and Biodas. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.